Systematic review identifies colchicine's effectiveness in reducing MACE and myocardial infarction in CAD patients, suggesting potential for widespread use.
Key Points
Colchicine significantly lowers the rate of major adverse cardiovascular events in patients with coronary artery disease, improving patient outcomes.
In a meta-analysis of 11 trials with 19,618 patients, colchicine demonstrated reduced risks for MACE, myocardial infarction, and coronary revascularization.
Randomized controlled trials assessing colchicine's effects used risk ratios to evaluate cardiovascular outcomes and address heterogeneity among studies.
Findings highlight the potential of colchicine for secondary prevention in cardiovascular disease, but further research is needed to confirm safety and efficacy.